Interview with Chen Chun Lin, Co-Chairman, Medicilon/MPI Preclinical Research…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move…
Medicilon/MPI Preclinical Research Shanghai
Last updated: 13.02.2014
Address: 585 Chuanda Road, Pudong New AreaShanghai, 201200,China
Tel: +86 21 31268381
Web: http://www.medicilon-mpi.com/
Company description
As a newly formed joint venture located in China, Medicilon/MPI Preclinical Research Shanghai provides a portfolio of preclinical discovery and development services to pharmaceutical and biotechnology companies.
Medicilon/MPI Preclinical Research Shanghai has brought together the best of its parent companies, Shanghai Medicilon and MPI Research, to assure top quality, on-time GLP and non-GLP studies.
Products and services
toxicology services
Interviews
Related
China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
China / PhIRDA’s Song Ruilin on Strengthening Drug Supervision Capacity & Promoting Pharma Innovation
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks…
China / CDE’s Drug Evaluation Report 2020: Part 1
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s…
China / Fosun Sales up 20%; MNC Price Manoeuvres Lead to Growth; Bayer Sees ‘Golden Age’ Ahead
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli…
China / Striving for First-In-Class Drug Innovation with New Patent Law
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric…
China / Hong Chow Leaves Roche for Big New Role at Merck
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…
China / Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
China / First CAR-T Approval; AZ & Bayer Take VBP Hit; Lonza Boosts Manufacturing Capacity
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
China / New Country President for MSD Amid Changes at HQ & Access Challenges
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…
China / A New Era of Reform Transforming Regulatory Professionals
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
